Issue: November 2017
October 13, 2017
1 min read
Save

Functional outcomes after reverse TSA did not differ between 135°, 155° neck-shaft angle constructs

Issue: November 2017
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Reuben Gobezie

NEW ORLEANS — Results presented at the American Shoulder and Elbow Surgeons Annual Meeting showed no significant differences in functional outcomes between patients who received either a 135° or 155° humeral implant during reverse shoulder arthroplasty.

Reuben Gobezie, MD, and colleagues compared range of motion and functional outcomes at 2 years postoperatively among 100 patients who underwent reverse shoulder arthroplasty with either a 135° humeral implant (n=50) or a 155° humeral implant (n=50) for treatment of rotator cuff arthropathy.

Gobezie noted patients in the 135° cohort and the 155° cohort had statistically significant improvements in all functional parameters, except for external rotation.

“When we compared the two, the 135° vs. the 155°, we saw no difference that was statistically significant in either of the groups for any of the parameters evaluated,” Gobezie said.

However, he noted radiographic evaluation showed significant differences in scapular notching.

“There was a 60% incidence in the 155° group vs. a 21% in the 135° group,” Gobezie said. “Most of these were grade 1 and [grade] 2.” – by Casey Tingle

Reference:

Shishani Y, et al. Paper #6. Presented at: American Shoulder and Elbow Surgeons Annual Meeting; Oct. 12-14, 2017; New Orleans.

Disclosure: Gobezie reports he is a board or committee member for the Arthroscopy Association of North America, the American Academy of Orthopaedic Surgeons, the American Shoulder and Elbow Surgeons and the Orthopaedic Research and Education Foundation; receives research support from Arthrex Inc. and Tornier; and receives IP royalties, is a paid consultant and is a paid presenter or speaker for Arthrex Inc.